Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease

被引：0
|
作者：
Teddy Kosoglou
Walter K. Kraft
Bharath Kumar
Paul Statkevich
Fengjuan Xuan
Lei Ma
Lisa K. Jennings
James E. Schiller
Ronald B. Langdon
David L. Cutler
机构：
[1] Merck Sharp & Dohme Corp.,Department of Pharmacology and Experimental Therapeutics
[2] Thomas Jefferson University,Clinical Pharmacology, Merck Research Laboratories
[3] University of Tennessee Health Science Center,undefined
[4] Merck Sharp & Dohme Corp.,undefined
来源：
European Journal of Clinical Pharmacology | 2012年 / 68卷
关键词：
Vorapaxar; SCH 530348; PAR-1; Renal disease; Pharmacokinetics; Pharmacodynamics;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1049 / 1056
页数：7
相关论文
共 50 条
  • [1] Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease
    Kosoglou, Teddy
    Kraft, Walter K.
    Kumar, Bharath
    Statkevich, Paul
    Xuan, Fengjuan
    Ma, Lei
    Jennings, Lisa K.
    Schiller, James E.
    Langdon, Ronald B.
    Cutler, David L.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (07) : 1049 - 1056
  • [2] Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment
    Statkevich, Paul
    Kosoglou, Teddy
    Preston, Richard A.
    Kumar, Bharath
    Xuan, Fengjuan
    Trusley, Craig
    Schiller, James E.
    Langdon, Ronald B.
    Cutler, David L.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (11) : 1501 - 1508
  • [3] Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects
    Kosoglou, Teddy
    Reyderman, Larisa
    Tiessen, Renger G.
    van Vliet, Andre A.
    Fales, Robert R.
    Keller, Robert
    Yang, Bo
    Cutler, David L.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (03) : 249 - 258
  • [4] Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects
    Teddy Kosoglou
    Larisa Reyderman
    Renger G. Tiessen
    André A. van Vliet
    Robert R. Fales
    Robert Keller
    Bo Yang
    David L. Cutler
    European Journal of Clinical Pharmacology, 2012, 68 : 249 - 258
  • [5] Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment
    Paul Statkevich
    Teddy Kosoglou
    Richard A. Preston
    Bharath Kumar
    Fengjuan Xuan
    Craig Trusley
    James E. Schiller
    Ronald B. Langdon
    David L. Cutler
    European Journal of Clinical Pharmacology, 2012, 68 : 1501 - 1508
  • [6] Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin
    Teddy Kosoglou
    Yali Zhu
    Fengjuan Xuan
    Laura Black
    Amy O. Johnson-Levonas
    Monika Martinho
    Paul Statkevich
    David L. Cutler
    European Journal of Clinical Pharmacology, 2012, 68 : 1509 - 1516
  • [7] Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin
    Kosoglou, Teddy
    Zhu, Yali
    Xuan, Fengjuan
    Black, Laura
    Johnson-Levonas, Amy O.
    Martinho, Monika
    Statkevich, Paul
    Cutler, David L.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 68 (11) : 1509 - 1516
  • [8] Vorapaxar, an Oral PAR-1 Receptor Antagonist, Does Not Affect the Pharmacokinetics of Rosiglitazone
    Kosoglou, Teddy
    Kumar, Bharath
    Statkevich, Paul
    Schiller, James E.
    Kantesaria, Bhavna
    Hanson, Mary E.
    Sisk, Christine McCrary
    Cutler, David L.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2015, 4 (01): : 56 - 62
  • [9] The Influence of Multiple-Dose Vorapaxar, an Oral PAR-1 Receptor Antagonist, on the Single-Dose Pharmacokinetics and Pharmacodynamics of Digoxin
    Kosoglou, Teddy
    Zhu, Yali
    Statkevich, Paul
    Xuan, Fengjuan
    Schiller, James E.
    Johnson-Levonas, Amy O.
    Cutler, David L.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2013, 2 (01): : 90 - 98
  • [10] Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease
    Small, D. S.
    Wrishko, R. E.
    Ernest, C. S., II
    Ni, L.
    Winters, K. J.
    Farid, N. A.
    Li, Y. G.
    Brandt, J. T.
    Salazar, D. E.
    Borel, A. G.
    Kles, K. A.
    Payne, C. D.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2009, 34 (05) : 585 - 594
12345